Overview
ADPT market data
Price History
ADPT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.39 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.14 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -20.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $11.92 – $26.16 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.9B · P/B 11.33 · P/S 12.75.
Company News
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5Benzinga · Aug 4, 2026, 12:12 PM
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22Benzinga · Jul 30, 2026, 5:20 PM
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28Benzinga · Jul 30, 2026, 3:34 PM
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25Benzinga · Jul 30, 2026, 1:48 PM
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25Benzinga · Jul 30, 2026, 9:49 AM
UPDATE: Adaptive Biotechnologies Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $71.553M Beat $65.886M EstimateBenzinga · Jul 29, 2026, 9:17 PM
Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M EstimateBenzinga · Jul 29, 2026, 8:06 PM
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% RunThe Motley Fool · Jul 13, 2026, 11:00 AM
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20Benzinga · Jul 9, 2026, 4:45 PM
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22Benzinga · Jun 29, 2026, 2:00 PM